Previous 10 | Next 10 |
2024-02-25 14:12:12 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips In almost every situation, investors should stay away from penny stocks . They’re extremely speculative and they tend to facilitate delusions of grandeur. To be sure, there’s ...
BioLineRx Announces Acceptance of Two Poster Presentations on APHEXDA® (motixafortide) for CD34+ Hematopoietic Stem Cell (HSC) Mobilization in Patients with Multiple Myeloma at the 2024 Tandem Meetings of ASTCT® and CIBMTR® PR Newswire Results include pharmaco...
2023-12-29 16:26:31 ET More on biolinerx BioLineRx: Still A Buy, With Some Questions biolinerx GAAP EPS of -$0.01 BioLineRx announces closing of exclusive license agreement with GloriaBio For further details see: BioLineRx files for a $250M mixed securiti...
BioLineRx Announces First Patient Dosed in Phase 1 Clinical Trial Evaluating Motixafortide for CD34+ Hematopoietic Stem Cell Mobilization for Gene Therapies in Sickle Cell Disease PR Newswire - Proof-of-concept study is initial step toward goal of identifying more efficient...
2023-12-04 18:42:54 ET Summary BioLineRx gains approval for a blood cancer drug that aids in stem cell transplantation. Motixafortide, the flagship drug, shows promising results in mobilizing blood stem cells and in combination with other treatments for pancreatic cancer. Fina...
2023-12-02 23:25:30 ET Summary BioLineRx is a biopharmaceutical company specializing in cancer and rare disease therapies. The company's main product, Aphexda, was FDA-approved for stem cell mobilization in multiple myeloma patients. BioLineRx's low cash reserves and need for ...
2023-11-20 13:54:04 ET BioLineRx Ltd. (BLRX) Q3 2023 Earnings Conference Call November 20, 2023 10:00 PM ET Company Participants John Lacey - Head of IR & Corporate Communications Phil Serlin - CEO Holly May - President of BioLineRx USA Mali Zeevi - CFO ...
2023-11-20 08:24:45 ET Losers: Syntec Optics Holdings ( OPTX ) -15% . Safe and Green Development Corp ( SGD ) -14% . Plus Therapeutics ( PSTV ) -14% reports new interim reSPECT-GBM phase 2 trial data at the society for NeuroOncology annual meeting. ...
BioLineRx Reports Third Quarter 2023 Financial Results and Recent Corporate and Portfolio Updates PR Newswire - Received FDA Approval of APHEXDA® (motixafortide) in Combination with Filgrastim (G-CSF) to Mobilize Hematopoietic Stem Cells for Collection and Subsequent Auto...
AERWINS Technologies Inc. (AWIN) is expected to report for Q1 2024 Minera IRL Ltd ADR (MRLLY) is expected to report for quarter end 2023-09-30 SmileDirectClub, Inc. - Ordinary Shares - Class A (SDCCQ) is expected to report $-0.1 for Q3 2023 NextPlay Technologies Inc. (NXTP) is expecte...
News, Short Squeeze, Breakout and More Instantly...
BioLineRx Ltd. Company Name:
BLRX Stock Symbol:
NASDAQ Market:
BioLineRx Announces Poster Presentation on Economic Model Data for APHEXDA® (motixafortide) as part of CD34+ Hematopoietic Stem Cell Mobilization in Patients with Multiple Myeloma at ISPOR 2024 PR Newswire - Presentation Today, Monday, May 6, 2024 in Atlanta , Geo...
BioLineRx Announces Poster Presentation on Apheresis Center Efficiency and CXCR4 Antagonists including APHEXDA® (motixafortide) in Patients with Multiple Myeloma at the ASFA 2024 Annual Meeting PR Newswire TEL AVIV, Israel , April 17, 2024 /PRNewswire/ --...
BioLineRx Accesses Second Tranche of $20 Million Under Previously Announced $40 Million Non-Dilutive Debt Financing Agreement PR Newswire - Proceeds to be used to further accelerate uptake of APHEXDA® in stem cell mobilization, life-cycle expansion activities in sic...